Skip to main content
. 2021 Oct 11;22(6):823. doi: 10.3892/ol.2021.13084

Figure 6.

Figure 6.

Validation of dysregulated mRNA transcripts in AML. (A) mRNA expression of FAM124B, HPDL, MPO and P2RY1 in the healthy control and the AML groups. ***P<0.001. (B) Protein expression levels of FAM124B, HPDL, MPO and P2RY1 in the healthy control and the AML groups (left). The relative protein expression levels are shown as a gray values normalized to β-actin (right). *P<0.05, **P<0.01, ***P<0.001. (C) Relative mRNA expression of FAM124B, HPDL, MPO and P2RY1 in the TK6, MOLM-13 and OCI-AML2 cell lines. *P<0.05, **P<0.01 vs. TK6 cells. (D) Relative mRNA expression of FAM124B, HPDL, MPO and P2RY1 in the low- and high-risk groups. *P<0.05, **P<0.01, ***P<0.001. ΔCq values were normalized to GAPDH. FAM124B, family with sequence similarity 124 member B; HPDL, 4-hydroxyphenylpyruvate dioxygenase-like protein; MPO, myeloperoxidase; P2RY1, purinergic receptor P2Y1; Cq, quantification cycle.